Top 5 Drug Type | Count |
---|---|
Small molecule drug | 7 |
Proteolysis-targeting chimeras (PROTAC) | 5 |
circular RNA | 1 |
Chemical drugs | 1 |
Degradable Molecular Glue | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism BPTF inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date01 May 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Chimeric Natural Killer Receptor-Universal T Cells(Fujian Medical University) | Steroid Refractory Graft Versus Host Disease More | Phase 1 |
Exosome of Mesenchymal Stem Cells(Fujian Medical University) | Multiple Organ Failure More | Clinical |
Koumine Hydrochloride | Rheumatoid Arthritis More | IND Approval |
DC-BPi-11 ( BPTF ) | Leukemia More | Preclinical |
cNEK6 | Pancreatic Ductal Adenocarcinoma More | Preclinical |